stockrowWindtree Therapeutics, Inc.
WINT Healthcare Biotechnology
- EPS
- +99.5%
- Free cash flow
- +1.12%
Quarter to September 2025, against a year earlier
Follow WINT
Alert me
Windtree Therapeutics, Inc. (WINT) EV/Sales
As of 6 November 2026, Windtree Therapeutics, Inc. (WINT) trades at a EV/Sales of 63.8×. Over the past ten years it has ranged from 15.5× (September 2023) to 145,871,991× (March 2015); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 223× | (99.99%) |
| FY2018 | 1,696,180× | 256.56% |
| FY2017 | 475,702× | (31.90%) |
| FY2016 | 698,571× | (98.78%) |
| FY2015 | 57,073,004× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2019 | 223× | 17.62% |
| Jun 2019 | 190× | 149.75% |
| Mar 2019 | 75.9× | (100.00%) |
| Dec 2018 | 1,696,180× | 76.23% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VIVS VivoSim Labs, Inc. compare | −8.4× |
| EOCN Eocene Ltd. compare | −3.1× |
| APVO Aptevo Therapeutics Inc. compare | −0.4× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| HCWB HCW Biologics Inc. compare | 1.1× |
| WINT Windtree Therapeutics, Inc. | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)